These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The medical merry-go-round: drugs for 1998 are new but not novel. Gilden D GMHC Treat Issues; 1997-1998 Winter; 12(1):18-25. PubMed ID: 11364984 [TBL] [Abstract][Full Text] [Related]
5. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038 [No Abstract] [Full Text] [Related]
6. Fortovase approved: new saquinavir formulation. James JS AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907 [TBL] [Abstract][Full Text] [Related]
7. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens. Barreiro P; Oller V; Soriano V; Nuñez M; Rodríguez-Rosado R; González-Lahoz J J Acquir Immune Defic Syndr; 2001 Apr; 26(4):391-2. PubMed ID: 11317086 [No Abstract] [Full Text] [Related]
10. Efavirenz (Sustiva) on fast-track for FDA accelerated approval. Food and Drug Administration. Baker R BETA; 1998 Jul; ():9. PubMed ID: 11365571 [TBL] [Abstract][Full Text] [Related]
11. Saquinavir (Fortovase or Invirase). Res Initiat Treat Action; 2000 Mar; 6(1):24-5. PubMed ID: 11708182 [No Abstract] [Full Text] [Related]
12. A comparative study reveals that a regimen containing sustiva provides an effective alternative to protease inhibitor-based therapy. J Assoc Nurses AIDS Care; 2002; 13(6):82-3. PubMed ID: 12469547 [No Abstract] [Full Text] [Related]
13. New formulation of saquinavir (Fortovase) is more effective. Tam CW Fac Notes (New Orleans La); 1998; 10(2):11. PubMed ID: 11365126 [TBL] [Abstract][Full Text] [Related]
14. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment. AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967 [TBL] [Abstract][Full Text] [Related]